Atheroscleroses, Coronary
Conditions
Brief summary
To assess whether vulnerable coronary plaques have more uptake of 68Ga-Dotatate than non-vulnerable plaques.
Interventions
OTHER68Ga-Dotatate PET/CT
One 68Ga-Dotatate PET/CT to determine uptake of tracer in the arterial wall.
Sponsors
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Aged 50 years and older * Underwent CCTA imaging within 78 weeks from the screening visit * Either CAD-RADS 4 or higher or 0/1 on CCTA. * Able to provide written informed consent
Exclusion criteria
* History of chronic kidney disease stage 3b - 5, defined as a CKD-EPI value of \< 45 ml/min/1,73m2. * CVD events/revascularization in history * Malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator. * Chronic or recent (\< 1 month) infections and/or clinical signs of acute infection. * History of auto-immune diseases. * Standard contra-indications to 68Ga-Dotatate PET, and CT based on physicians experience and current practices. * Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study. * Elevated liver enzymes (\> 2 ULN of liver transaminases), acute liver failure or known liver disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference in TBRmax | 1 day | Difference of target to background ratio (TBR)max in the coronary arteries between groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between TBRmax and FAI. | 1 day | Correlation of TBRmax with fat attenuation index, a specific CCTA parameter of vascular inflammation. |
Countries
Netherlands
Outcome results
None listed